CTLA4 and neoplasm: These humanized monoclonal antibodies target inhibitory receptors (e.g., CTLA-4, PD-1, LAG-3, TIM-3) and ligands (PD-L1) expressed on T lymphocytes, antigen-presenting cells, and tumor cells and elicit an anti-tumor response by stimulating the immune system (1, 2).